Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Strikingly different atheroprotective effects of apolipoprotein A-I in early- versus late-stage atherosclerosis
Author: Morton, J.
Bao, S.
Vanags, L.
Tsatralis, T.
Ridiandries, A.
Siu, C.
Ng, K.
Tan, J.
Celermajer, D.
Ng, M.
Bursill, C.
Citation: JACC: Basic to Translational Science, 2018; 3(2):187-199
Publisher: Elsevier
Issue Date: 2018
ISSN: 2452-302X
Statement of
Jamie Morton, Shisan Bao, Laura Z. Vanags, Tania Tsatralis, Anisyah Ridiandries, Chung-Wah Siu, Kwong-Man Ng, Joanne T.M. Tan, David S. Celermajer, Martin K.C. Ng, Christina A. Bursill
Abstract: Preclinical studies have shown benefit of apolipoprotein A-I (apoA-I)/high-density lipoprotein (HDL) raising in atherosclerosis; however, this has not yet translated into a successful clinical therapy. Our studies demonstrate that apoA-I raising is more effective at reducing early-stage atherosclerosis than late-stage disease, indicating that the timing of HDL raising is a critical factor in its atheroprotective effects. To date, HDL-raising clinical trials have only been performed in aged patients with advanced atherosclerotic disease. Our findings therefore provide insight, related to important temporal aspects of HDL raising, as to why the clinical trials have thus far been largely neutral.
Keywords: Atherosclerosis, cholesterol; high-density lipoproteins
Rights: © 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
RMID: 0030086605
DOI: 10.1016/j.jacbts.2017.11.004
Grant ID:
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.